SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesmarket

028300 (028300) News

Follow 028300 (028300) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol 028300 Asset market Sector Markets 90 days 1 Updated Sep 22, 2026, 01:46 PM UTC Open live news feed
M FDA grants conditional acceptance of LYRFIGTU brand name Elevar Therapeutics says the FDA granted conditional acceptance of LYRFIGTU as the brand name for lirafugratinib, which is under FDA Priority Review. REGULATION | Sep 22, 2026, 01:46 PM UTC